The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model - Takeaways - MDSpire

The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model

Share

  • 1

    DA5-CH, a dual GLP-1/GIP receptor agonist, demonstrated superior effectiveness over Tirzepatide and Exendin-4 in a rat model of Parkinson's disease.

  • 2

    DA5-CH protected dopaminergic neurons in the substantia nigra more effectively than Tirzepatide or Exendin-4.

  • 3

    Dopamine levels in the striatum were normalized by DA5-CH, while Exendin-4 showed limited effectiveness and Tirzepatide was ineffective.

  • 4

    DA5-CH significantly reduced inflammation markers IL-6 and TNF-α in the lesioned striatum compared to Exendin-4 and Tirzepatide.

  • 5

    The levels of α-synuclein in the substantia nigra were reduced by DA5-CH, indicating its potential as a therapeutic for neurodegenerative disorders.

Original Source(s)

The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model

  • by Zhang Lingyu, Feng Peng, Zhong Wanting, Jin Qianqian, Zijuan Zhang, Bo Bai, Guofang Xue, Christian Hölscher

  • May 5, 2026

Related Content

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody

  • May 5, 2026

  • 5 min
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...